Navigation Links
Reportlinker Adds Markets for Emerging Pharmaceutical Technologies
Date:5/11/2011

NEW YORK, May 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Markets for Emerging Pharmaceutical Technologies

http://www.reportlinker.com/p0492944/Markets-for-Emerging-Pharmaceutical-Technologies.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

REPORT HIGHLIGHTS

*

As a segment, therapeutic vaccines recorded $19.3 billion in 2010, a figure that is expected to grow to $31.9 billion by 2015, demonstrating a compound annual growth rate (CAGR) of 10.6%.

*

Treatment for infectious disease continues to advance, growing from a 2010 figure of $86.5 billion to $116 billion by 2015, a compound annual growth rate (CAGR) of 6.1%. Large and important areas including Hepatitis and HIV/AIDS will drive this increase.

*

Biomarkers, as an enabling element within drug development, will experience explosive growth, increasing from a current $13.5 billion to $33.3 billion in 2015, a 19.8% compound annual growth rate (CAGR) for the forecast period. The increased application of biomarkers in nonclinical, clinical and point of care areas in addition to stratifying patient populations to increase targeted applications of medicine will drive the increase.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This study provides a comprehensive analysis of emerging pharmaceutical technologies on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the market for therapeutic drug products in the emerging technologies segment. Individual products are forecast on a global basis, as are overall segments. Forecasts and trends are developed from a cross-reference of data points, gleaned from proprietary industry sources, company publications, industry benchmarking, and other divergent data sources to arrive at a cogent and coordinated forecast.

REASONS FOR DOING THE STUDY

For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with where opportunity exists and ends with how to effectively execute to capture profit from opportunity.

The emerging technologies therapeutic market presents the largest of all opportunities in representative disease subsegments. Market growth has been spurred by the introduction of differentiated therapies due to novel mechanisms of action, such as P2Y12 inhibitors and factor Xa inhibitors.

This study investigates one of the most important market drivers: the introduction of combination therapies, which are expected to continue to contribute substantially to market growth through the forecast period. This report analyzes emerging markets, by disease segment. Continued growth is expected in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil and Russia.

This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and technologies, strategies for accessing emerging markets, and specific disease segments and geographies in order to allocate resources and make effective decisions.

SCOPE OF REPORT

Current and projected product forecasts during the forecast period (2010 to 2015) are discussed. As well, new products approved in 2009 and 2010 by the FDA, and those products expected to be approved within the forecast period are projected. 2010 is an estimated figure, except where actual results have been reported, due to the release timing of the report. For all areas, including the very large markets segments such as infectious disease and cardiovascular, specific mechanisms of action are discussed in detail.

The report includes analysis of leading and emerging competitors in the current worldwide emerging technologies market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define their specific product strategies employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care. Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to advance within the forecast period.

Market figures are based on revenues at the manufacturers' level and are projected at 2010-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products, and projected changes in the prevalence, diagnosis, and scripting rates for certain diseases.

Included in this report are forecasts by product, product category, and by company from 2009 through 2015. The study is arranged to offer an overview of the Emerging Technologies market accompanied by product, company, geography, and mechanism of action with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data, for each disease subsegment.

Excluded from this report are over-the-counter (OTC) medications, and other consumables that do not require a physician's prescription.

Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.

All market share data presented are on a global basis, unless specifically noted.

INTENDED AUDIENCE

This report is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, investor consultants and anyone interested in the Emerging Technologies market, its products, its industry participants and its future.

The importance of identifying overall market trends, product opportunities, emerging geographies, M&A opportunities and insights that provide guidance for sales growth or defensive moves cannot be overstated for a variety of constituents, including:

* Established companies in the industry will benefit from the contents, including corporate strategy, sales and marketing, business development, and R&D

* Emerging biotechnology players in the segment must understand specific opportunities for out-licensing, originating from the elements of differentiation of their therapeutic drug as compared to leading, competitive, and emerging therapies. As well, market forecasts can support investment, provided a thorough and detailed substantiation is provided for the market forecast, as is found in this study

* Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunity and risks that are being encountered in the industry, in a product and company specific analysis

* Equity analysts are provided detailed forecasts for the next 5 years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.

METHODOLOGY AND INFORMATION SOURCES

In-depth interviews were conducted with leading experts in the field who are executives in companies, industry analysts, and leading medical practitioners in the field.

The overall emerging technologies sector is comprised of a variety of fast growing and independent segments. For completeness, the current and forecasted markets are comprised of the total market opportunity for each respective segment. Within each subsection, there is a detailed forecast for each driving mechanism, or relevant area of growth.

Information to prepare this report was obtained from participating and emerging companies in the emerging technologies area; American Heart Association; the National Heart, Lung, and Blood Institute; articles published in medical journals such as American Heart Journal, Circulation, Journal of Emerging Technologies Pharmacology, Lancet, and others; the World Health Organization and other government agencies; literature searches; annual reports; 10Ks; and others. Population estimates are based on those reported by the international data base of the U.S. Census Bureau.

Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.

CHAPTER ONE: INTRODUCTION 1

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

SCOPE OF REPORT 2

INTENDED AUDIENCE 3

METHODOLOGY AND INFORMATION SOURCES 3

RELATED REPORTS 4

BCC ONLINE SERVICES 4

DISCLAIMER 5

CHAPTER TWO: SUMMARY 6

SUMMARY TABLE GLOBAL EMERGING TECHNOLOGIES

FORECAST BY AREA, THROUGH 2015 ($ MILLIONS) 6

SUMMARY FIGURE GLOBAL EMERGING TECHNOLOGIES

FORECAST BY AREA, 2009-2015 ($ MILLIONS) 7

SUMMARY (CONTINUED) 8

CHAPTER THREE: THERAPEUTIC VACCINES 9

OVERVIEW 9

TABLE 1 GLOBAL MARKET FOR THERAPEUTIC VACCINES,

THROUGH 2010 ($ MILLIONS) 9

KEY EVENTS IN THE THERAPEUTIC VACCINE MARKET 10

EXPANDING SEGMENT: PROPHYLACTIC CANCER

VACCINES 10

VACCINE OPPORTUNITY SLACKENING DUE TO

OVERCAPACITY 10

CELL CULTURE AND ADJUVANT TECHNOLOGY

ENABLE THERAPEUTIC VACCINES 11

TABLE 2 MARKET FORECAST FOR THERAPEUTIC VACCINES,

THROUGH 2015 ($ MILLIONS) 11

LEADING VACCINE BRANDS 12

TABLE 3 LEADING VACCINE BRANDS, THROUGH 2010 ($

MILLIONS) 12

HEPATITIS VACCINES 12

PRODUCTS SUMMARY 12

TABLE 4 MARKET FOR LEADING VACCINES: HEPATITIS

SEGMENT, THROUGH 2010 ($ MILLIONS) 13

MARKET DYNAMICS 13

INFLUENZA VACCINES 14

TABLE 5 MARKET FOR LEADING VACCINES: INFLUENZA

SEGMENT, THROUGH 2010 ($ MILLIONS) 14

H1N1 SWINE FLU 15

MARKET DYNAMICS 15

PNEUMONIA VACCINES 16

MARKET DYNAMICS 16

MENINGITIS VACCINES 17

TABLE 6 MARKET FOR LEADING VACCINES: MENINGITIS

SEGMENT, THROUGH 2010 ($ MILLIONS) 17

MARKET DYNAMICS 18

OTHER VACCINES 18

HUMAN PAPILLOMAVIRUS (HPV) VACCINES 18

MARKET DYNAMICS 18

Market Dynamics (Continued) 19

EMERGING TARGETS IN THERAPEUTIC VACCINES 20

THE NEW VACCINE STRATEGY: THERAPEUTIC

VACCINES 20

Therapeutic Vaccines with Traditional Strategies 20

Antigen/Whole Cell Vaccines 20

Therapeutic Vaccines with Novel and Advanced

Strategies 20

Dendritic Cell Vaccines 20

Cytolytic Viral Vaccines 21

DNA Vaccines 21

AFFiTOPE/AFFiTOME 22

Beta Amyloid 22

Somatostatin GHRH 23

Plasmid Encorders 24

Telomerase Endogenous Reverse Transcriptase (TERT) 25

PIPELINE ANALYSIS 26

INTRODUCTION 26

RECENTLY APPROVED PRODUCTS 26

Menveo 26

TABLE 7 PRODUCT PROFILE SUMMARY: MENVEO 26

Menveo (Continued) 27

Prevnar 13vPnC 28

TABLE 8 PRODUCT PROFILE SUMMARY: PREVNAR 13VPNC 28

Prevnar 13vPnC (Continued) 29

Cervarix 30

TABLE 9 PRODUCT PROFILE SUMMARY: CERVARIX 30

Synflorix 31

TABLE 10 PRODUCT PROFILE SUMMARY: SYNFLORIX 31

Synflorix (Continued) 32

Ixiaro/Jespect 33

TABLE 11 PRODUCT PROFILE SUMMARY: IXIARO/JESPECT 33

Provenge 34

TABLE 12 PRODUCT PROFILE SUMMARY: PROVENGE 34

Provenge (Continued) 35

Provenge (Continued) 36

DEVELOPMENT STAGE THERAPEUTIC VACCINES 36

MenB 37

TABLE 13 PRODUCT PROFILE SUMMARY: MENB 37

COMPANY ANALYSIS 38

OVERVIEW 38

GLAXOSMITHKLINE 38

Product and Pipeline Portfolio 38

TABLE 14 PIPELINE SUMMARY: GSK 38

Company Strategy 39

MERCK 40

Product and Pipeline Portfolio 40

TABLE 15 PIPELINE SUMMARY: MERCK 40

Company Strategy 41

NOVARTIS 42

Product and Pipeline Portfolio 42

TABLE 16 PIPELINE SUMMARY: NOVARTIS 42

Product and Pipeline … (Continued) 43

Company Strategy 44

Company Strategy (Continued) 45

PFIZER 46

Product and Pipeline Portfolio 46

TABLE 17 PIPELINE SUMMARY: PFIZER 46

Company Strategy 47

SANOFI-AVENTIS 48

Product and Pipeline Portfolio 49

TABLE 18 PIPELINE SUMMARY: SANOFI-AVENTIS 49

Company Strategy 50

Company Strategy (Continued) 51

Company Strategy (Continued) 52

CHAPTER FOUR: INFECTIOUS DISEASE TREATMENTS 53

INTRODUCTION 53

TABLE 19 GLOBAL MARKET FOR INFECTIOUS DISEASE,

THROUGH 2010 ($ MILLIONS) 54

PRODUCT SUMMARY AND MARKET 54

BACTERIAL DISEASE 54

Overview 54

TABLE 20 CURRENT MARKET BY DRUG CLASS FOR BACTERIAL

DISEASE, THROUGH 2010 ($ MILLIONS) 54

Cephalosporins 55

Penicillins 55

Fluoroquinolones 55

TABLE 21 MARKET FOR LEADING PRODUCTS: BACTERIAL

DISEASE, THROUGH 2010 ($ MILLIONS) 56

VIRAL INFECTIONS 57

TABLE 22 MARKET BY DRUG CLASS FOR VIRAL INFECTION,

THROUGH 2010 ($ MILLIONS) 57

AIDS/HIV 57

Nucleoside Reverse Transcriptase Inhibitor (NRTI) 58

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) 58

Protease Inhibitors 58

TABLE 23 MARKET FOR LEADING PRODUCTS: VIRAL INFECTION

DISEASE, THROUGH 2010 ($ MILLIONS) 59

VACCINES 59

TABLE 24 MARKET BY DRUG CLASS FOR VACCINES, THROUGH

2010 ($ MILLIONS) 59

Hepatitis 60

Hepatitis A and E 60

Hepatitis B 60

Hepatitis C 60

Hepatitis C (Continued) 61

Hepatitis D (with B) 62

Hepatitis G 62

Interferons 62

Antivirals 62

TABLE 25 MARKET FOR LEADING PRODUCTS: VACCINETREATABLE

DISEASE, THROUGH 2010 ($ MILLIONS) 63

FUNGAL INFECTIONS 63

TABLE 26 MARKET BY DRUG CLASS FOR FUNGAL INFECTIONS,

THROUGH 2010 ($ MILLIONS) 63

Fungal Infections (Continued) 64

TABLE 27 MARKET FOR LEADING PRODUCTS: FUNGAL DISEASE,

THROUGH 2010 ($ MILLIONS) 65

TRENDS AND INNOVATIONS IN INFECTIOUS DISEASE 65

KEY TRENDS IN INFECTIOUS DISEASE 65

Large and Growing Opportunity: Drug Resistant

Infections 66

Emerging Markets Open HIV/AIDS Drugs to Fast

Growth 66

Hepatitis C as Major Need Matched with Novel

Last-Stage Compounds 66

Novel Vaccines Drive Future Sales Growth 66

Flu Pandemics Offer Latent Opportunity 67

MARKET FORECAST 67

TABLE 28 MARKET FORECAST FOR INFECTIOUS DISEASE,

THROUGH 2015 ($ MILLIONS) 68

PIPELINE ANALYSIS 68

TABLE 29 PRODUCTS IN DEVELOPMENT BY STAGE AND

INFECTIOUS DISEASE SEGMENT (NUMBER OF

DEVELOPMENTAL PRODUCTS) 69

PROFILES OF KEY PRODUCTS IN DEVELOPMENT 69

RECENTLY APPROVED DRUGS 69

Doribax 69

TABLE 30 PRODUCT PROFILE SUMMARY: DORIBAX 69

Isentress 70

TABLE 31 PRODUCT PROFILE SUMMARY: ISENTRESS 70

Prezista 71

TABLE 32 PRODUCT PROFILE SUMMARY: PREZISTA 71

Prezista (Continued) 72

Selzentry 73

TABLE 33 PRODUCT PROFILE SUMMARY: SELZENTRY 73

Eraxis 74

TABLE 34 PRODUCT PROFILE SUMMARY: ERAXIS 74

Gardasil 75

TABLE 35 PRODUCT PROFILE SUMMARY: GARDASIL 75

Ceftobiprole 76

TABLE 36 PRODUCT PROFILE SUMMARY: CEFTOBIPROLE 76

Cervarix 77

TABLE 37 PRODUCT PROFILE SUMMARY: CERVARIX 77

Cervarix (Continued) 78

Menveo 79

TABLE 38 PRODUCT PROFILE SUMMARY: MENVEO 79

PHASE III DEVELOPMENT STAGE DRUGS 80

Albuferon 80

TABLE 39 PRODUCT PROFILE SUMMARY: ALBUFERON 80

Tygacil 81

TABLE 40 PRODUCT PROFILE SUMMARY: TYGACIL 81

Tygacil (Continued) 82

Numax 83

TABLE 41 PRODUCT PROFILE SUMMARY: NUMAX 83

Telaprevir 84

TABLE 42 PRODUCT PROFILE SUMMARY: TELAPREVIR 84

Vicriviroc 85

TABLE 43 PRODUCT PROFILE SUMMARY: VICRIVIROC 85

Prevnar 13vPnC 86

TABLE 44 PRODUCT PROFILE SUMMARY: PREVNAR 13VPNC 86

COMPANY ANALYSIS 87

ABBOTT 87

Company Overview 87

Products and Services 87

Company Strategy 88

BRISTOL-MYERS SQUIBB 88

Company Overview 88

Products and Services 89

Company Strategy 89

GILEAD SCIENCES 90

Company Overview 90

Products and Services 90

Company Strategy 91

GLAXOSMITHKLINE 91

Company Overview 91

Products and Services 92

Company Strategy 92

JOHNSON & JOHNSON 93

Company Overview 93

Products and Services 93

Company Strategy 94

MERCK 94

Company Overview 95

Products and Services 95

Company Strategy 96

NOVARTIS 96

Company Overview 96

Products and Services 97

Company Strategy 97

PFIZER 98

Company Overview 98

Products and Services 99

Company Strategy 99

SANOFI-AVENTIS 99

Company Overview 99

Products and Services 100

Company Strategy 100

Company Strategy (Continued) 101

CHAPTER FIVE: BIOMARKERS 102

INTRODUCTION 102

TABLE 45 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2010 ($

MILLIONS) 103

ENABLING ADVANCEMENTS DRIVING MARKET GROWTH 103

BIOMARKERS DRIVE SPEED, COST AND QUALITY

IMPROVEMENTS ACROSS THE DRUG DEVELOPMENT

SPECTRUM 103

BIOMARKERS APPLICATIONS: DRUG DEVELOPMENT 104

Safety/Toxicology Biomarkers 105

Dose Selection and Dose Optimization 105

Improved Measurement of Therapeutic Efficacy 105

Outcome Biomarkers and Surrogate Endpoints 105

EARLY-STAGE CLINICAL TRIAL APPLICATIONS 106

LATE-STAGE CLINICAL TRIAL APPLICATIONS 107

Phase III 107

Phase IV 107

BIOMARKERS: CHALLENGES AND OPPORTUNITIES 107

SUMMARY 107

CLINICAL VALIDITY: REQUIREMENTS 108

BIOMARKER OPPORTUNITIES 108

PRODUCT SUMMARY AND MARKET 108

GENOMICS 108

TABLE 46 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2010 ($

MILLIONS) 109

IMAGING 109

PROTEOMICS 110

BIOINFORMATICS 110

OTHER 111

Metabonomics 111

BIOMARKER ADOPTION BY THE PHARMACEUTICAL

INDUSTRY 111

GROWTH DRIVERS AND RESISTORS 111

FACTORS INFLUENCING BIOMARKER ADOPTION IN

CLINICAL TRIALS 111

CLINICAL TRIAL BENEFITS: COST AND RISK AVOIDANCE 112

IMPACT OF DRUG FAILURE IN LAST-STAGE CLINICAL

TRIALS 112

Merck: Vicriviroc 112

ADDITIONAL CAPABILITIES BY LARGE SERVICE

PLAYERS 113

TECHNOLOGICAL ADVANCEMENTS IN GENOMICS AND

PROTEOMICS 113

BIOMARKER MARKET FORECAST 114

TABLE 47 GLOBAL BIOMARKER MARKET FORECAST, THROUGH

2015 ($ MILLIONS) 114

REGULATORY ENVIRONMENT 114

INTRODUCTION 114

ROLE OF THE FOOD AND DRUG ADMINISTRATION 114

TABLE 48 FDA GUIDELINES FOR BIOMARKER APPLICATIONS 115

EUROPEAN MEDICINES AGENCY 116

REGULATORY IMPACT ON DRUG SAFETY 117

INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING 117

APPROVED PATENT ANALYSIS 117

TABLE 49 ANNUAL PATENTS FILED AND APPROVED WITH

BIOMARKER CLAIMS IN US, EUROPE, JAPAN, THROUGH 2010 118

COMPETITIVE LANDSCAPE 118

LATE STAGE CLINICAL TRIALS: COMPETITIVE

POSITIONING 118

TABLE 50 CURRENT GLOBAL MARKET FOR TOTAL CLINICAL

STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH

2010 ($ MILLIONS) 119

TABLE 51 GLOBAL MARKET FORECAST FOR CLINICAL STAGE

BIOMARKERS, THROUGH 2015 ($ MILLIONS) 120

APPLICATION BY THERAPY AREA 120

TABLE 52 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER

DELIVERY 120

TABLE 52 (CONTINUED) 121

TABLE 53 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS

BY THERAPEUTIC AREA, THROUGH 2010 ($ MILLIONS) 121

Oncology 121

TABLE 54 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:

ONCOLOGY 122

Cardiovascular 122

TABLE 55 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:

CARDIOVASCULAR 123

Central Nervous System 123

TABLE 56 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS

DISEASE 124

Immunology 124

TABLE 57 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:

IMMUNOLOGY 125

REPRESENTATIVE EXAMPLES WITHIN CANCER AND

IMMUNOLOGY 125

Cancer 125

Elesclomol: Synta 125

Immunology 126

Benlysta: Human Genome Sciences 126

Cancer 126

Hereptin: Roche 126

Expedition and Identity 126

Alzheimer's Trial: Eli Lilly 126

LEADING COMPANIES 127

AFFYMETRIX, INC 127

Company Overview 127

Products and Services 127

Company Strategy 127

BANYAN BIOMARKERS, INC 128

Company Overview 128

Products and Services 128

Company Strategy 128

BG MEDICINE, INC 129

Company Overview 129

Products and Services 129

Company Strategy 129

BIOPHYSICAL CORP 130

Company Overview 130

Products and Services 130

Company Strategy 130

BIOSYSTEMS INTERNATIONAL INC 131

Company Overview 131

Products and Services 131

Company Strategy 131

CAPRION PROTEOMICS INC 132

Company Overview 132

Products and Services 132

Company Strategy 132

CLINICAL DATA, INC 133

Company Overview 133

Products and Services 133

Company Strategy 133

CORRELOGIC SYSTEMS, INC 134

Company Overview 134

Products and Services 134

Company Strategy 134

EPIGENOMICS AG 135

Company Overview 135

Products and Services 135

Company Strategy 135

GENEDATA AG 136

Company Overview 136

Products and Services 136

Company Strategy 137

GENEGO, INC 137

Company Overview 137

Products and Services 137

Company Strategy 137

GENENEWS LTD 138

Company Overview 138

Products and Services 138

Company Strategy 139

CHAPTER SIX: NEXT-GENERATION CARDIOVASCULAR THERAPIES 140

SUMMARY 140

TABLE 58 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE,

THROUGH 2015 ($ MILLIONS) 141

EMERGING DRUG CLASSES 142

P2Y12 AND FACTOR XA INHIBITORS 142

TABLE 59 CARDIOVASCULAR MARKET FORECAST BY DRUG

CLASS, THROUGH 2015 142

TABLE 59 (CONTINUED) 143

Effient (Prasugrel): a Leading P2Y12 Antagonist 143

TABLE 60 P2Y12 MARKET GROWTH AND SHARE, THROUGH 2010 ($

MILLIONS) 144

TABLE 61 PY12 MARKET FORECAST, THROUGH 2015 ($ MILLIONS) 144

TABLE 62 FACTOR XA CURRENT MARKET GROWTH AND SHARE ($

MILLIONS) 145

TABLE 63 FACTOR XA MARKET FORECAST, THROUGH 2015 ($

MILLIONS) 145

P2Y12 Inhibitors and Antagonists 145

Factor Xa Inhibitors 146

Cholesterol-Ester Transfer Protein (CETP) Inhibitor 146

TABLE 64 CETP INHIBITORS IN ACTIVE DEVELOPMENT 147

KEY RECENT EVENTS IN THE CARDIOVASCULAR MARKET 147

P2Y12 IS A PROVEN TARGET FOR MULTIPLE

INDICATIONS; APPROVALS ARE EXPECTED 147

PLAVIX METABOLIZER 2C19 TRIGGERS US WARNING 147

VALTURNA FIRST TO RECEIVE US APPROVAL AS

COMBINATION THERAPY FOR HYPERTENSION 148

VALTURNA FIRST TO RECEIVE US APPROVAL AS

COMBINATION THERAPY FOR HYPERTENTION 149

ANTICOAGULANTS ENABLE NEW PRODUCT APPROVALS,

IN PARTICULAR FACTOR XA 150

APOB-100 AS A NOVEL TREATMENT FOR

HYPERLIPIDEMIA 151

INCREASED DRIVE TO ESTABLISH AND EXTEND HIGH

HDL CHOLESTEROL LEVELS 151

SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT 152

TABLE 65 MARKET VALUE OF RECENTLY APPROVED DRUGS,

2009-2015 ($ MILLIONS) 153

TABLE 66 SUMMARY PIPELINE FORECAST, 2009-2015 ($ MILLIONS) 153

INDUSTRY STRUCTURE 153

TABLE 67 CARDIOVASCULAR MARKET SEGMENTS, SIZE, GROWTH

AND SHARE, THROUGH 2010 ($ MILLIONS) 154

MARKET TRENDS 155

TABLE 68 PATENT EXPIRATION OF CARDIOVASCULAR DRUGS,

THROUGH 2015 ($ MILLIONS) 156

Massive Patent Expiration is a Growth Opportunity for

Generics 156

Market Expansion via Disease Prevention is the Future of

Cardio Care 157

Atrial Fibrillation is a Large and Emerging Disease State 157

Atrial Fibrillation … (Continued) 158

Combination Therapies are Synergistic Revenue

Generators 159

PIPELINE ANALYSIS 160

TABLE 69 APPROVED PRODUCT FORECAST, 2010 AND 2015 ($

MILLIONS) 160

MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT 160

2010 APPROVALS IN CARDIOVASCULAR THERAPY 161

MULTAQ (DRONEDARONE): SANOFI-AVENTIS 161

TABLE 70 MULTAQ SNAPSHOT 161

XARELTO (RIVAROXABAN): BAYER SCHERING/J&J 162

TABLE 71 XARELTO SNAPSHOT 163

EFFIENT/EFIENT (PRASUGREL): ELI LILLY/DAIICHI

SANKYO 164

TABLE 72 EFFIENT SNAPSHOT 164

RENDIX (DABIGATRAN): BOEHRINGER INGELHEIM 165

TABLE 73 RENDIX SNAPSHOT 166

RECENTLY FILED/PRE-REGISTRATION COMPOUNDS 167

APIXABAN: BRISTOL-MYERS SQUIBB (BMS)/PFIZER 167

TABLE 74 APIXABAN SNAPSHOT 167

BRILINTA (TICAGRELOR/AZD6140): ASTRAZENECA 168

TABLE 75 BRILINTA SNAPSHOT 169

CERTRIAD (ROSUVASTATIN/ FENOFIBRIC ACID):

ASTRAZENECA/ABBOTT 170

TABLE 76 CERTRIAD SNAPSHOT 170

PHASE II/III COMPOUNDS 171

LCZ696: NOVARTIS 171

TABLE 77 LCZ696 SNAPSHOT 171

EDOXABAN (DU-176B): DAIICHI SANKYO 172

TABLE 78 EDOXABAN (DU-176B) SNAPSHOT 172

SCH 530348 – MERCK 173

TABLE 79 SCH530348 SNAPSHOT 173

TYRISA/DARAPLADIB: GSK 174

TABLE 80 TYRISA SNAPSHOT 174

BETRIXABAN: PORTOLA/MERCK 175

TABLE 81 BETRIXABAN SNAPSHOT 176

PIPELINE ANALYSIS BY COMPANY 177

TABLE 82 PFIZER'S CARDIOVASCULAR PIPELINE 177

TABLE 83 SANOFI-AVENTIS' CARDIOVASCULAR PIPELINE 177

TABLE 84 NOVARTIS' CARDIOVASCULAR PIPELINE 177

TABLE 85 MERCK'S CARDIOVASCULAR PIPELINE 178

TABLE 86 BMS' CARDIOVASCULAR PIPELINE 178

TABLE 87 ASTRA-ZENECA'S CARDIOVASCULAR PIPELINE 178

COMPANY PROFILES 179

SUMMARY 179

TABLE 88 COMPANY REVENUE AND MARKET SHARE ANALYSIS,

THROUGH 2010 ($ MILLIONS) 179

TABLE 89 MARKET FORECAST BY COMPANY, THROUGH 2015 ($

MILLIONS) 180

ASTRAZENECA 181

Business Overview 181

Leading Products 181

Crestor 181

Atacand 182

Certriad 182

Corporate Strategy 182

BRISTOL-MYERS SQUIBB COMPANY 183

Business Overview 183

Leading Products 183

Plavix 183

Apixaban 183

Corporate Strategy 183

MERCK & CO, INC 184

Business Overview 184

Leading Products 184

Vytorin 184

Zetia 185

Cozaar 185

Hyzaar 186

Zocor 186

Corporate Strategy 186

PFIZER, INC 187

Business Overview 187

Leading Products 187

Lipitor 187

Norvasc 188

Revatio 188

Corporate Strategy 188

SANOFI AVENTIS 189

Business Overview 189

Leading Products 189

Plavix 189

Lovenox 190

Multaq 190

Corporate Strategy 191

CHAPTER SEVEN: LEADING OPHTHALMIC TREATMENTS 192

TABLE 90 GLOBAL OPHTHALMIC MARKET FORECAST BY

DISEASE, THROUGH 2015 ($ MILLIONS) 192

LEADING OPHTHALMIC TREATMENTS (CONTINUED) 193

OVERVIEW 194

ESTABLISHED DRUG CLASSES IN OPHTHALMOLOGY 194

EMERGING DRUG CLASSES 194

VEGF-Trap Eye 194

Combination Therapies 194

COMPETITION BETWEEN VEGF INHIBITORS IN WET AMD 195

TABLE 91 NOTABLE EVENTS IN LUCENTIS VERSUS AVASTIN:

PREVIOUS AND EXPECTED 195

TABLE 91 (CONTINUED) 196

Expected Outcome of CATT Trial: Avastin v Lucentis 196

PIPELINE ANALYSIS 197

TABLE 92 APPROVED PRODUCT SALES FORECAST, 2008-2014 ($

MILLIONS) 197

TABLE 93 PIPELINE SALES FORECAST, 2008-2014 ($ MILLIONS) 198

MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT 198

STRINGENT REGULATORY PATHWAY EXISTS FOR DRYEYE

DISEASE 198

SUSTAINED DELIVERY IS A COMMON TRAIT AMONG

LEADING PRODUCTS IN DEVELOPMENT 199

SIRNA THERAPIES IN DEVELOPMENT EXPERIENCE

SYSTEMIC SAFETY CONCERNS 200

INDUSTRY STRUCTURE 201

MARKET CONCENTRATION AND PRICE SENSITIVITY 202

TABLE 94 COMPANY BY DISEASE CLASS, 2009 REVENUE ($

MILLIONS) 203

COMPETITIVE FACTORS 203

TABLE 95 LARGE-REVENUE BRANDED DRUG SALES COMING

OFF-PATENT, 2009 204

MARKET TRENDS 204

Demographics Offer Tremendous Long-run Opportunity 204

TABLE 96 REVENUE GROWTH OF OPHTHALMOLOGY AS

COMPARED TO TOTAL PHARMACEUTICAL MARKET, 2005-2010

(% YEAR-OVER-YEAR REVENUE GROWTH) 205

An Increasingly Challenging Global Reimbursement

Environment 205

Sustained Drug Delivery is the Future of Retinal Care 205

Payment Structures Important to Revenue Uptake and

Peak Sales 206

Fundamental Patient Need: Blindness or Impaired Vision

among the Most Debilitating Diseases 206

Combination Therapies Promise Improved Therapeutic

Response 207

Expansion of Prescription Therapies to Rural

Communities 207

TABLE 97 NUMBER OF US HOSPITALS PROVIDING OPHTHALMIC

CARE (NUMBER/%) 208

TABLE 98 NUMBER OF TRAINED, LICENSED, AND CERTIFIED

OPHTHALMOLOGISTS 208

TABLE 99 REVENUE AND SHARE BY LEADING OPHTHALMIC

PLAYERS, 2009 ($ MILLIONS/%) 208

TABLE 100 MARKET ANALYSIS BY DISEASE, 2008 AND 2009 ($

MILLIONS/%) 209

TABLE 101 LEADING OPHTHALMIC THERAPIES, TOTAL SEGMENT,

2009 ($ MILLIONS/%) 209

NOTABLE MERGERS, ACQUISITIONS AND

TRANSACTIONS 210

Roche/Genentech 210

Alcon/Novartis 210

Transaction Summary 210

Proposed Terms of Purchase 210

Proposed Terms … (Continued) 211

Integration Challenges and Opportunities 212

Fovea/Sanofi-Aventis 212

DETAILED PIPELINE REVIEW 213

2009 APPROVALS IN OPHTHALMOLOGY THERAPY 213

Acuvail 213

TABLE 102 SNAPSHOT OF ACUVAIL 213

Clinical Results 213

Bepreve 214

TABLE 103 SNAPSHOT OF BEPREVE 214

Clinical Results 214

Besivance 215

TABLE 104 SNAPSHOT OF BESIVANCE 215

Ozurdex 216

TABLE 105 SNAPSHOT OF OZURDEX 216

Ozurdex (Continued) 217

Zirgan 218

OPHTHALMIC DRUGS IN ADVANCED DEVELOPMENT 218

PHASE III 218

VEGF Trap-Eye 218

TABLE 106 SNAPSHOT OF VEGF TRAP-EYE 219

Clinical Results 219

Iluvien 220

TABLE 107 SNAPSHOT OF ILUVIEN 220

Clinical Results 220

Luveniq 221

TABLE 108 SNAPSHOT OF LUVENIQ 221

PHASE II 222

Ecabet 222

TABLE 109 SNAPSHOT OF ECABET 222

Clinical Results 222

Androgen Tears 223

TABLE 110 SNAPSHOT OF ANDROGEN TEARS 223

PIPELINE ANALYSIS BY COMPANY 224

TABLE 111 ALCON'S OPHTHALMIC PIPELINE 224

TABLE 112 ALLERGAN'S OPHTHALMIC PIPELINE 224

TABLE 113 PFIZER'S OPHTHALMIC PIPELINE 225

TABLE 114 NOVARTIS' OPHTHALMIC PIPELINE 225

TABLE 115 MERCK OPHTHALMIC PIPELINE 225

TABLE 116 SANTEN OPHTHALMIC PIPELINE 225

COMPANY PROFILES 226

SUMMARY 226

ALCON 227

Business Overview 227

Leading Products 227

Pataday 227

Vigamox 227

Nevanac 228

Triesence 228

Tobradex 228

Travatan and Travatan Z 228

Azopt 228

Azarga 228

Duotrav 229

Corporate Strategy 229

ALLERGAN, INC 229

Business Overview 229

Leading Products 229

Restasis and Others 229

Lumigan and Others 230

Corporate Strategy 230

GENENTECH/ROCHE 231

Business Overview 231

Leading Products 231

Lucentis 231

Avastin (Bevacizumab) 232

Corporate Strategy 232

INSPIRE PHARMACEUTICALS, INC 232

Business Overview 233

Leading Products 233

Prolacria (Diquafosol Tetrasodium) 233

Additional Products 233

Corporate Strategy 234

MERCK 234

Business Overview 234

Leading Products 234

Intraocular Pressure Therapies 234

Corporate Strategy 235

NOVARTIS 235

Business Overview 235

Leading Products 235

Lucentis 235

Visudyne 235

Company Strategy 236

OPKO HEALTH 236

Business Overview 236

Leading Products 236

Bevasiranib 236

Civamide 237

Doxovir 237

Company Strategy 237

PFIZER 238

Business Overview 238

Leading Products 238

Xalatan (Latanoprost Ophthalmic Solution) 238

Corporate Strategy 238

POTENTIA PHARMACEUTICALS 239

Business Overview 239

Leading Products 239

POT-4 239

Corporate Strategy 239

QLT INC 240

Business Overview 240

Leading Products 240

Visudyne 240

Corporate Strategy 240

REGENERON 241

Business Overview 241

Leading Products 241

VEGF-Trap Eye 241

Corporate Strategy 241

SANOFI-AVENTIS 242

Business Overview 242

Leading Products 242

Prednisporin 242

FOV2302 242

Corporate Strategy 243

SANTEN SEIYAKU 243

Business Overview 243

Leading Products 244

Hyalein 244

Cravit/Oftaquix 244

Corporate Strategy 244

CHAPTER EIGHT: CNS: NEXT-GENERATION MECHANISMS OF

ACTION 245

TABLE 117 GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY

DISEASE CLASS, THROUGH 2015 ($ MILLIONS) 245

CNS: NEXT-GENERATION MECHANISMS …CONTINUED) 246

KEY RECENT EVENTS IN THE CENTRAL NERVOUS SYSTEM

MARKET 247

2009 FDA PEDIATRIC ADVISORY COMMITTEE ON

PRESCRIPTION OF ANTIPSYCHOTICS 247

GROWTH SEEN VIA PURSUIT OF ADDITIONAL

INDICATIONS VERSUS NCE APPROVALS 247

ALZHEIMER'S DRUGS IN JAPAN OPEN UP LARGE

OPPORTUNITIES, DRIVEN BY DEMOGRAPHICS 248

SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT 248

TABLE 118 RECENTLY APPROVED AND PIPELINE FORECAST,

2009-2015 ($ MILLIONS) 248

MARKET TRENDS 249

OVERALL MARKET FLAT: HIGHER MIX OF GENERICS

OFFSET BY HIGHER VOLUME 249

SIGNIFICANT IMPACT OF PATIENT ADVOCACY GROUPS

IN CNS DISEASE 249

GROWTH SEEN VIA PURSUIT OF ADDITIONAL

INDICATIONS VERSUS NCE APPROVALS 249

IMPROVING PERFORMANCE IN DEPRESSION

TREATMENTS 250

ALZHEIMER'S THERAPY CONTINUES TO RECEIVE LARGE

AND IMPORTANT INVESTMENT 250

TABLE 119 PATENT EXPIRATION OF CENTRAL NERVOUS SYSTEM

DRUGS, 2010 AND 2015 ($ MILLIONS) 251

TABLE 120 MARKET SHARE BY LEADING CENTRAL NERVOUS

SYSTEM PLAYERS, 2010 ($ MILLIONS/%) 251

TABLE 120 (CONTINUED) 252

TABLE 121 LARGEST REVENUE GENERATING THERAPIES IN THE

CENTRAL NERVOUS SYSTEM DISEASE, THROUGH 2010 ($

MILLIONS) 252

CHAPTER NINE: MARKETS BY DISEASE 253

SUMMARY OF MARKET DYNAMICS 253

TABLE 122 GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY

DISEASE CLASS, THROUGH 2015 ($ MILLIONS) 254

PSYCHIATRY 254

MARKET DYNAMICS 254

Market Dynamics (Continued) 255

TABLE 123 GLOBAL PSYCHIATRY MARKET, THROUGH 2015 ($

MILLIONS) 255

TABLE 123 (CONTINUED) 256

DEPRESSION 256

Market Dynamics 256

TABLE 124 GLOBAL DEPRESSION MARKET, THROUGH 2015 ($

MILLIONS) 257

Generic Drug Trends: Depression 257

TABLE 125 GLOBAL DEPRESSION MARKET, THROUGH 2015 ($

MILLIONS) 257

TABLE 125 (CONTINUED) 258

MULTIPLE SCLEROSIS AND PARKINSON'S 258

MARKET DYNAMICS 258

TABLE 126 GLOBAL MS AND PARKINSON'S MARKET THROUGH

2010 ($ MILLIONS) 259

GENERIC DRUG TRENDS: PARKINSON'S 259

TABLE 127 GLOBAL MS AND PARKINSON'S MARKET, THROUGH

2015 ($ MILLIONS) 260

EPILEPSY/CONVULSIONS 260

MARKET DYNAMICS 260

TABLE 128 GLOBAL EPILEPSY MARKET, THROUGH 2010 ($

MILLIONS) 261

TABLE 129 GLOBAL EPILEPSY MARKET, THROUGH 2015 ($

MILLIONS) 261

GENERIC DRUG TRENDS: EPILEPSY/CONVULSIONS 262

ALZHEIMER'S 262

MARKET DYNAMICS 262

TABLE 130 GLOBAL ALZHEIMER'S MARKET, THROUGH 2010 ($

MILLIONS) 263

TABLE 131 GLOBAL ALZHEIMER'S MARKET, THROUGH 2015 ($

MILLIONS) 263

TABLE 131 (CONTINUED) 264

GENERIC DRUG TRENDS: ALZHEIMER'S 264

ADHD AND NARCOLEPSY 264

MARKET DYNAMICS 264

TABLE 132 GLOBAL ADHD/NARCOLEPSY MARKET, THROUGH 2010

($ MILLIONS) 265

TABLE 133 GLOBAL ADHD/NARCOLEPSY MARKET, THROUGH 2015

($ MILLIONS) 265

GENERIC DRUG TRENDS: ADHD/NARCOLEPSY 266

MIGRAINE AND OTHER CNS DISEASE 266

MARKET DYNAMICS 266

TABLE 134 GLOBAL MIGRAINE MARKET, THROUGH 2015 ($

MILLIONS) 266

TABLE 135 GLOBAL OTHER CENTRAL NERVOUS SYSTEM

MARKET, THROUGH 2015 ($ MILLIONS) 267

PIPELINE ANALYSIS 267

TABLE 136 APPROVED PRODUCT FORECAST, 2009-2015 ($

MILLIONS) 268

MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT 268

KEY TRENDS IN RESEARCH AND DEVELOPMENT 268

SNRIs Improve the Baseline Performance of Leading

Depression Therapies 268

New Products Provide Larger Opportunities Compared to

Product Extensions 269

Combination Products Yield Greater Therapeutic

Response 269

Alzheimer's Therapy Continues to Receive Large and

Important Investment 269

KEY PRODUCTS UNDER MAJOR CNS DISORDERS 270

Schizophrenia 270

Depression 270

Alzheimer's 271

Parkinson's Disease 272

Epilepsy 272

Insomnia 272

Attention Deficit Hyperactivity Disorder 272

Other Indications 273

2009 APPROVALS IN CENTRAL NERVOUS SYSTEM THERAPY 273

PHASE III AND PENDING APPROVAL COMPOUNDS 273

TABLE 137 BAPINEUZUMAB (AAB–001): ELAN/WYETH/PFIZER 273

Phase III and Pending … (Continued) 274

TABLE 138 TELCAGEPANT (MK–0974): MERCK 275

Phase III and Pending … (Continued) 276

TABLE 139 SOLANEZUMAB (LY2062430): ELI LILLY 277

TABLE 140 SEMAGACESTAT (LY450139): ELI LILLY 278

TABLE 141 VILAZODONE: CLINICAL DATA 279

RECENTLY APPROVED/MARKETED DRUGS 280

TABLE 142 STEDESA/ZEBINIX (ESLICARBAZEPINE ACETATE):

DAINIPPON SUMITOMO (FORMERLY SEPRACOR) 280

TABLE 143 INTUNIV (GUANFACINE): SHIRE 281

TABLE 144 TREXIMET (SUMATRIPTAN AND NAPROXEN):

GSK/POZEN 282

TABLE 145 PRISTIQ (DESVENLAFAXINE): PFIZER/WYETH 283

Recently Approved/… (Continued) 284

TABLE 146 VIMPAT (LACOSAMIDE): UCB/SCHWARZ PHARMA 285

TABLE 147 DEVELOPMENTAL PRODUCT FORECAST 2009-2015 ($

MILLIONS) 286

CHAPTER TEN: COMPANY PROFILES 287

SUMMARY 287

COMPANIES 287

ABBOTT LABORATORIES 287

Business Overview 287

Therapeutic Areas 288

TABLE 148 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 288

Corporate Strategy 288

ALLERGAN, INC 288

Business Overview 288

Therapeutic Areas 289

TABLE 149 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 289

Corporate Strategy 289

ASTELLAS PHARMA, INC 289

Business Overview 289

Therapeutic Areas 289

TABLE 150 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 290

Corporate Strategy 290

ASTRAZENECA 290

Business Overview 290

Therapeutic Areas 291

TABLE 151 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 291

Corporate Strategy 291

BAYER AG 292

Business Overview 292

Therapeutic Areas 292

TABLE 152 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 293

Corporate Strategy 293

BIOGEN IDEC (FUMAPHARM AG) 293

Business Overview 293

Therapeutic Areas 293

TABLE 153 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 294

Corporate Strategy 294

ELI LILLY & CO 294

Business Overview 294

Therapeutic Areas 294

TABLE 154 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 295

Corporate Strategy 295

FOREST LABORATORIES, INC 295

Business Overview 296

Therapeutic Areas 296

TABLE 155 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 296

Corporate Strategy 296

GLAXOSMITHKLINE (GSK) 297

Business Overview 297

Therapeutic Areas 297

TABLE 156 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 297

Corporate Strategy 297

JOHNSON & JOHNSON 298

Business Overview 298

Therapeutic Areas 298

TABLE 157 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 298

Corporate Strategy 299

MERCK & CO, INC 299

Business Overview 299

Therapeutic Areas 300

TABLE 158 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 300

Corporate Strategy 300

NOVARTIS AG (NOVARTIS PHARMACEUTICALS) 300

Business Overview 300

Therapeutic Areas 301

TABLE 159 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 301

Corporate Strategy 301

PFIZER, INC 301

Business Overview 302

Therapeutic Areas 302

TABLE 160 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 302

Corporate Strategy 302

SANOFI-AVENTIS 303

Business Overview 303

Therapeutic Areas 303

TABLE 161 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 304

Corporate Strategy 304

SHIRE PHARMACEUTICALS GROUP, PLC 304

Business Overview 304

Therapeutic Areas 304

TABLE 162 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 305

Corporate Strategy 305

Business Overview 305

Therapeutic Areas 306

TABLE 163 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 306

Corporate Strategy 306

TEVA PHARMACEUTICAL INDUSTRIES LTD 306

Business Overview 306

Therapeutic Areas 307

TABLE 164 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 307

Corporate Strategy 307

WATSON PHARMACEUTICALS, INC 307

Business Overview 308

Therapeutic Areas 308

TABLE 165 LEADING PRODUCTS AND REVENUE, 2009 ($

MILLIONS) 308

Corporate Strategy 308

CHAPTER ELEVEN: CANCER TRENDS: EVOLVING THERAPIES 309

INTRODUCTION 309

TRENDS IN ONCOLOGY DRUG DEVELOPMENT 309

PERSONLIZED TREATMENTS BECOMING STANDARD OF

CARE 309

VACCINES IMPROVE ACCESS TO IMMUNE RESPONSE 310

COST TO SERVE IS NEXT FRONTIER OF

DIFFERENTIATION 310

ONCOLOGISTS REPLACE DRUG COMPANIES TO DELIVER

COMBINATION THERAPY 311

TABLE 166 ONCOLOGY MARKETS BY TYPE OF THERAPY,

THROUGH 2010 ($ MILLIONS) 311

MARKET ANALYSIS BY DRUG CLASS 311

KEY RECENT EVENTS IN THE CANCER MARKET 312

FDA WITHDRAWS BREAST CANCER INDICATION FOR

AVASTIN 312

MYLOTARG WITHDRAWN BASED ON BOTH SAFETY AND

EFFICACY CONCERNS 312

JEVTANA APPROVED FOR METASTATIC HORMONEREFRACTORY

PROSTATE CANCER 313

STIMUVAX PHASE III TRIALS RESUMED BY MERCK

SERONO 313

FDA CONTINUES GARDASIL REVIEW 314

NEOPLASIA THERAPY 314

COMPETITIVE DYNAMICS OF NEOPLASIA THERAPY 314

TABLE 167 ONCOLOGY MARKETS BY DRUG CLASS, THROUGH 2010

($ MILLIONS) 315

LEADING NEOPLASIA THERAPY BRANDS 316

TOTAL NEOPLASIA THERAPY MARKET 316

TABLE 168 2010 ONCOLOGY MARKETS BY LARGEST

THERAPEUTIC DRUGS, THROUGH 2010 ($ MILLIONS) 316

NEOPLASIA THERAPY MAB MARKET ANALYSIS 317

MARKET DYNAMICS 317

PRODUCT REVIEW 317

Erbitux (Cetuximab) 317

Nexavar (Sorafenib) 318

NEOPLASIA THERAPY PROTEIN KINASE INHIBITORS 319

MARKET DYNAMICS

To order this report:

Drug and Medication Industry: Markets for Emerging Pharmaceutical Technologies

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016 Jeffrey Zucker , ... Trials, will present at this year,s Summit for Clinical Operations ... in Miami, FL. Zucker will discuss ... study execution, supporting SCOPE,s "Improving Site Study Activation and Performance" ... Thursday, Feb. 25 at 11:05 a.m. --> ...
(Date:2/11/2016)... , February 11, 2016 F ... answers at the ... a world-leading provider of scientific, technical and medical information products and services, ... to evidence-based, peer reviewed clinical information via a mobile device. Elsevier designed ... ClinicalKey for Nursing. The new app is available in Android ...
(Date:2/11/2016)... Feb. 11, 2016 Exactus Pharmacy Solutions, ... high-quality specialty pharmacy care for those suffering from ... has achieved full Specialty Pharmacy Accreditation from URAC, ... to promoting health care quality through accreditation, education ... --> The URAC accreditation process demonstrates a ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 12, 2016 , ... The Journal of Pain Research has seen ... SJR uses data taken from the Scopus database (Elsevier B.V.) and is a measure ... by the journal over a three year period and also the importance of the ...
(Date:2/11/2016)... ... 11, 2016 , ... The president released a FY 2017 budget request on ... more of the cost burden to military beneficiaries. , MOAA’s president, retired Air ... budget as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , ...
(Date:2/11/2016)... ... February 11, 2016 , ... Hall Integrative Health and ... for their simultaneous grand openings in March. All seven practices are set to ... wondering, is reversing diabetes possible? According to this 2011 CNN article it is ...
(Date:2/11/2016)... ... 2016 , ... Thermi™, a world leader in thermistor-regulated energy ... promotions of Allison Kelly to executive vice president of the company’s new North ... North American capital sales, and Wendy Oseas to vice president of global marketing. ...
(Date:2/11/2016)... ... 11, 2016 , ... Atlantic Information Services, Inc. (AIS) is ... Case Study for Plans and Purchasers.” Executives from Intel Corp. and Providence Health ... value-based health benefits program Connected Care, will discuss the challenges they faced (and ...
Breaking Medicine News(10 mins):